SEC Form 4 · accession 0001562180-17-000234
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimi Iguchi
Officer — CFO, Secretary and Treasurer
Period of report
Jan 13, 2017
Accepted (ET)
Jan 13, 2017 · 3:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jan 13, 2017 | S | 10,000 | $53.92 | D | 66,498 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2This transaction was executed in multiple trades at prices ranging from $53.72 USD to $54.33 USD; the price reported above reflects the weighted average sale price.
- F3These shares include prior ESPP purchases.